Drug intelligence / Profile preview

LV-Visio-AMTRIX

Development stage: Unknown
Lead developer: TBF Génie Tissulaire
Administration: Ophthalmic

Overview

LV-Visio-AMTRIX is a tissue-engineered ophthalmic graft developed by TBF Génie Tissulaire. It consists of a double layer of amniotic membrane integrated into a ring of umbilical vessels containing Wharton's jelly, all processed using the proprietary AMTRIX technology. This biological product is designed to promote ocular surface healing, reduce inflammation, and provide analgesic effects. It is currently being evaluated in clinical trials for the treatment of resistant keratitis, trophic corneal ulcers, and recurrent macular holes. Additionally, it is used as a post-operative adjunct to facilitate recovery and manage pain following procedures such as corneal crosslinking for keratoconus and photorefractive keratectomy (PRK).

Brand names: Visio-AMTRIX
Other names: Amniotic Membrane Visio-AMTRIX

Beyond the preview

Go deeper on LV-Visio-AMTRIX.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LV-Visio-AMTRIX.

Explore the full profile